1. B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
- Author
-
Aliyah R. Sohani, Matija Snuderl, Judith A. Ferry, Ephraim P. Hochberg, Lawrence R. Zukerberg, Paola Dal Cin, Jeremy S. Abramson, Adam M. Ackerman, Yi Bin Chen, Olga K. Kolman, Jessie J. Hsu, Christiana E. Toomey, Nancy L. Harris, Alfred Ian Lee, Hang Lee, and Robert P. Hasserjian
- Subjects
Male ,Pathology ,Time Factors ,Gene Rearrangement, B-Lymphocyte, Heavy Chain ,Kaplan-Meier Estimate ,Polymerase Chain Reaction ,immune system diseases ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Child ,In Situ Hybridization, Fluorescence ,MYC Gene Rearrangement ,Aged, 80 and over ,Karyotype ,Middle Aged ,Burkitt Lymphoma ,Gene Expression Regulation, Neoplastic ,Treatment Outcome ,medicine.anatomical_structure ,Proto-Oncogene Proteins c-bcl-2 ,Female ,Lymphoma, Large B-Cell, Diffuse ,Anatomy ,Adult ,medicine.medical_specialty ,Lymphoma, B-Cell ,Adolescent ,Genes, Immunoglobulin Heavy Chain ,Biology ,World Health Organization ,Risk Assessment ,Article ,Immunophenotyping ,Pathology and Forensic Medicine ,Proto-Oncogene Proteins c-myc ,Young Adult ,Predictive Value of Tests ,Terminology as Topic ,medicine ,Humans ,B cell ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Retrospective Studies ,Cytogenetics ,Cancer ,Gene rearrangement ,medicine.disease ,Lymphoma ,Drug Resistance, Neoplasm ,Karyotyping ,Surgery ,Diffuse large B-cell lymphoma - Abstract
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as “double-hit” lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathological features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL). The clinical and pathological spectrum of this rare entity, including comparison to other high-grade B-cell neoplasms, has not been well defined. We conducted a retrospective analysis of clinical and pathologic features of 20 cases of DHL seen at our institution during a 5-year period. In addition, we performed case-control comparisons of DHL with BL and International Prognostic Index (IPI)-matched DLBCL. The 11 men and 9 women had a median age of 63.5 years (range 32-91). Six patients had a history of grade 1-2 follicular lymphoma (FL); review of the prior biopsy specimens in 2 of 5 cases revealed blastoid morphology. Eighteen patients had Ann Arbor stage 3 or 4 disease and all had elevated serum lactate dehydrogenase (LDH) levels at presentation. Extranodal disease was present in 17/20 (85%), bone marrow involvement in 10/17 (59%) and central nervous system (CNS) disease in 5/11 (45%). Nineteen patients were treated with combination chemotherapy, of whom 18 received rituximab and 14 received CNS-directed therapy. Fourteen patients (70%) died within 8 months of diagnosis. Median overall survival in the DHL group (4.5 months) was inferior to both BL (p=0.002) and IPI-matched DLBCL (p=0.04) control patients. Twelve DHL cases (60%) were classified as B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL, 7 cases (35%) as DLBCL, not otherwise specified, and 1 case as B-LBL. Distinguishing features from BL included expression of Bcl2 (p
- Published
- 2010
- Full Text
- View/download PDF